Disease-related cortical thinning in presymptomatic granulin mutation carriers

Sergi Borrego-Écija a,1, Roser Sala-Llonch b,1, John van Swieten c, Barbara Borroni d, Fermin Moreno e, Mario Masellis f, Carmela Tartaglia g, Caroline Graff h, Daniela Galimberti i,j, Robert LafSource Jr k, James B Rowe l, Elizabeth Finger m, Rik Vandenberghne n, Fabrizio Tagliavini o, Alexandre de Mendonça p, Isabel Santana q, Matthis Synofzik q,s, Simon Ducharme t,u, Johannes Levin v,w,x, Adrian Danek y, Alex Gerhard y, Markus Otto y, Chris Butler a, Giovanni Frisoni b,c,c, Sandro Sorbi d,d,e, Carolin Heller f,f, Martina Bocchetta f,f, David M Cash f,f, Rhian S Convery f,f, Katrina M Moore f,f, Jonathan D Rohrer f,f, Raquel Sanchez-Valle a,h,b, on behalf of the Genetic FTD Initiative GENFI

a Alzheimer’s disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
b Department of Biomedicine, Institute of Neuroscience, University of Barcelona, Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain
c Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands
d Centre for Neurodegenerative Disorders, Neurology Unit, Department of Experimental and Clinical Sciences, University of Brescia, Brescia, Italy
e Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Gipuzkoa, Spain
f Health Economics and Outcome Research, Louvain Research Institute, Université de Mons, Mons, Belgium
g Department of Clinical Neurosciences and Medical Research Council, Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom
h Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
i Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium
j Fondazione IRCCS Ca’ Granda, Ospedale Policlinico, Neurodegenerative Diseases Unit, Milan, Italy
k Department of Clinical Neurosciences and Medical Research Council, Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, United Kingdom
l Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
m Department of Cognitive Neurosciences, University of Milano-Bicocca, Monza, Italy
n Department of Clinical Neurology, University of Florence, Florence, Italy
o Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Don Carlo Gnocchi, Brescia, Italy
p Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands
q Department of Clinical Neurosciences, University of Toronto, Toronto, Ontario, Canada
r Biomedical, Surgical and Dental Sciences, University of Milan, Centro Dino Ferrari, Milan, Italy
s Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada
t Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Neurologico Carlo Besta, Milano, Italy
u Department of Clinical Neurology, University of Cambridge, Cambridge, UK
v Faculty of Medicine, University of Lisbon, Lisbon, Portugal
w Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Quebec, Canada
x Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands
y Faculty of Medicine, University of Coimbra, Coimbra, Portugal
z Faculty of Medicine, University of Edinburgh, Edinburgh, Scotland
{ Department of Clinical Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany
\( \text{German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany} \)
\( \text{Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Quebec, Canada} \)
\( \text{McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada} \)
\( \text{Department of Neurology, Ludwig-Maximilians-University, Munich, Germany} \)
\( \text{German Center for Neurodegenerative Diseases (DZNE), Site Munich, Munich, Germany} \)
\( \text{SyNergy, Munich Cluster for Systems Neurology, Munich, Germany} \)
\( \text{Faculty of Medical and Human Sciences, Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK} \)
\( \text{Department of Neurology, University of Ulm, Ulm, Germany} \)
\( \text{Department of Clinical Neurology, University of Oxford, Oxford, United Kingdom} \)
\( \text{Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy} \)
\( \text{Memory Clinic LANVIE-Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland} \)
\( \text{Department of Neuroscience, Psychology, Drug Research, and Child Health, University of Florence, Florence, Italy} \)
\( \text{Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Don Carlo Gnocchi, Florence, Italy} \)
\( \text{Dementia Research Centre, Department of Neurodegenerative Disease, Queen Square UCL Institute of Neurology, London, UK} \)

1 Corresponding author at: Alzheimer’s disease and other cognitive disorders Unit, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Villarroel, 170 08036 Barcelona, Spain.
E-mail address: rsanchez@clinic.cat (R. Sanchez-Valle).
2 These authors contributed equally.

https://doi.org/10.1016/j.nicl.2020.102540
Received 23 June 2020; Received in revised form 14 December 2020; Accepted 15 December 2020
Available online 29 December 2020
2213-1582/© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
1. Introduction

Frontotemporal dementia (FTD) is a clinically, genetically and pathologically heterogeneous group of neurodegenerative diseases characterized by behavioral and language impairment. FTD is a highly heritable disorder, with mutations in several genes causing genetic forms of the disease. Mutations in the granulin (GRN) gene were identified in 2006 as a cause of familial FTD with TAR-DNA binding protein 43 (TDP-43) inclusions (Baker et al., 2006; Cruts et al., 2006). The prevalence of GRN mutations has been estimated at 6% of all FTD patients and 20% of familial FTD (Cruts and Van Broeckhoven, 2008). The majority of FTD due to GRN mutations patients present a behavioral variant FTD, non-fluent primary progressive aphasia or corticobasal syndrome (Moore et al., 2019).

In 2010, a genome-wide association study revealed transmembrane protein 106B (TMEM106B) gene as a risk factor for FTD with TDP-43 inclusions (Van Deerlin et al., 2010). Further studies had replicated these findings, showing an extremely low presence of the TMEM106B minor allele in homozygosis in GRN patients, indicating that individuals who are homozygous for the minor TMEM106B allele are less likely to develop symptoms (Finch et al., 2011; Nicholson and Rademakers, 2016).

Previous work using structural MRI revealed that symptomatic GRN mutation carriers typically show a widespread but asymmetric pattern of grey matter (GM) loss, affecting frontal, temporal and parietal lobes (Beck et al., 2008; Fumagalli et al., 2018; Whitwell et al., 2009). Studies in presymptomatic GRN mutation carriers have shown divergent results, with many of them reporting no significant brain structural differences compared with noncarriers (Borroni et al., 2012, 2008; Caroppo et al., 2015; Cash et al., 2018; Olim et al., 2018; Panman et al., 2019; Piovani et al., 2014; Rohrer et al., 2015). TMEM106B variants have also been studied in the general population using neuroimaging, with the risk allele being related to reduced volume of the left temporal lobe in non-demented subjects (Adams et al., 2014). In this line, and complementing the structural findings, Premi et al. used functional MRI and found that, in GRN carriers, the TMEM106B risk haplotype was associated with decreased functional connectivity in the left frontoparietal network (Premi et al., 2014).

In a previous cross-sectional study with a limited number of subjects, we observed that presymptomatic GRN mutation carriers presented greater loss of cortical thickness (CTh) by age in temporal areas compared to noncarriers (Moreno et al., 2013). Here, we aimed to expand these previous findings by investigating the change in CTh in a much larger cohort of presymptomatic mutation carriers using data from the Genetic Frontotemporal Dementia Initiative (GENFI). We also aimed to investigate the potential influence of the TMEM106B genotype in the grey matter loss in GRN carriers.

2. Methods

2.1. Participants

We analyzed cross-sectional data from the GENFI study (Rohrer et al., 2015), Data Freeze 3. The GENFI cohort includes subjects at risk of genetic FTD, from centres across Europe and Canada (https://www.genfi.org/). Subjects in the cohort undergo a standardized clinical and neuropsychological assessment as well as an MRI exam once a year (Rohrer et al., 2013). Our work included the baseline data from 100 presymptomatic mutation carriers and 94 noncarriers from 54 different families. For each subject, sex, age, estimated years to onset (EYO) and education were obtained from the GENFI database. The EYO was computed considering the difference between the subject’s age and the average familial age of symptom onset. Asymptomatic status was ascertained based on relative’s interview, neurological examination and normality on behavioral scales and neuropsychological tests. Local ethics committees at each site approved the study and all participants provided written informed consent.

2.2. TMEM106B genetic analysis

TMEM106B rs1990622 (C/T) single nucleotide polymorphism was performed according to standard procedures (Premi et al., 2014) in 90 subjects: 46 presymptomatic GRN carriers and 44 noncarriers.

2.3. Demographic and clinical statistical analysis

Differences in the clinical and demographic data between carriers and presymptomatic carriers were assessed using t-test for continuous variables and chi-squared test was used for dichotomous data. Differences in demographics between TMEM106B genotypes were assessed with non-parametric tests (Fisher Test for dichotomous data and Kruskall-Wallis Test for continuous data).

2.4. Image acquisition and processing

Participants underwent a 1.1-mm isotropic resolution volumetric T1 MR imaging on a 3 T using the sequences defined within the GENFI consortium.

MRI images of all subjects were downloaded from GENFI database and processed using FreeSurfer version 6.0 (http://surfer.nmr.mgh.harvard.edu/), with the main goal of computing individual CTh surface maps. Briefly, the FreeSurfer pipeline includes skull stripping (Segonne et al., 2004), segmentation of the subcortical white matter and deep gray matter volumetric structures (Fischl et al., 2004, 2002), tessellation of boundaries, and definition of the transition between tissue classes. Then, CTh is calculated as the closest distance from the gray/white boundary to the gray/cerebrospinal fluid boundary at each vertex (Dale et al.,
3. Results

3.1. Demographic and genetic results

The demographic and genetic data of the 194 subjects are described in Table 1. The mean age at onset of the 54 different families included was 60.1 years (range 43–74.5 years). There were no differences in age, EYO, sex or education between groups. On average, presymptomatic mutation carriers presented an EYO of –13.0 years. No significant differences were found in TMEM106B haplotypes between groups. In both

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Demographic characteristics and TMEM106B genotype. EYO: Estimated Years to Onset, SD: standard deviation; ns: not significant, TMEM106B: transmembrane protein 106B.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noncarriers</td>
<td>GRN presymptomatic carriers</td>
</tr>
<tr>
<td>n = 94</td>
<td>n = 100</td>
</tr>
<tr>
<td>Age, years mean (SD)</td>
<td>47.5 (13.2)</td>
</tr>
<tr>
<td>EYO, years mean (SD)</td>
<td>–13.2 (14.9)</td>
</tr>
<tr>
<td>Sex male/female</td>
<td>51/43</td>
</tr>
<tr>
<td>Education, years mean (SD)</td>
<td>14.2 (3.8)</td>
</tr>
<tr>
<td>TMEM106B (rs1990622)</td>
<td>n = 44</td>
</tr>
<tr>
<td>C/C (%)</td>
<td>3 (6.8%)</td>
</tr>
<tr>
<td>T/T (%)</td>
<td>27 (61.4%)</td>
</tr>
<tr>
<td>TMEM106B haplotypes</td>
<td>0.472</td>
</tr>
</tbody>
</table>

3.2. Group differences in cortical thickness

There were no differences in CTh at the group level when comparing presymptomatic mutation carriers and noncarriers groups, neither with global measures nor with vertex-wise analyses. We hypothesized that this lack of difference might be consequence of the inclusion of subjects far from the predicted age at onset, and we also performed the whole-brain vertex-wise analysis between carriers and noncarriers in the subgroup of subjects nearest to the expected onset (EYO > -10), but no significant differences arose.

3.3. Correlation between cortical thickness and age

When we evaluated the CTh correlation with age at the whole-brain level, both presymptomatic mutation carriers and noncarriers showed a pattern of cortical thinning associated with age (r = -0.59 vs r = -0.53, both significant with p < 0.001), but no significant differences were observed between them at the whole brain level (p = 0.272) (Fig. 1).

3.4. Vertex-wise general linear models

When comparing carriers and noncarriers at the vertex-wise level with an interaction model, we identified a cluster with significant results (corrected p < 0.05) in the left superior frontal cortex (Fig. 2A). Age, gender, education and scanner were included as covariates. When studying the trajectories separately for each group within the significant ROI, we found that presymptomatic carriers showed a significant negative correlation between age and CTh (r = -0.57, p < 0.001), while noncarriers did not (r = -0.12, p = 0.265) (Fig. 2B). Additionally, we performed a multiple linear regression model within the ROI to quantify the effect of age education and gender into this result. Only Age and Age × group interaction were significant (p < 0.001, see Table 2).

3.5. Correlations between cortical thickness and EYO

Due to the presence of different GRN mutations that may present different ages of onset, we repeated the interaction analysis using EYO instead of actual age. We identified a cluster with significant differences between carriers and noncarriers (corrected p < 0.05) covering the right temporal cortex, the banks of superior temporal sulcus, the inferi-orparietal and the supramarginal gyrus. It is noticeable that these regions also appeared in the analysis with age, however they did not survive multiple comparisons. Again, we performed multiple linear regression models to predict the ROI-CTh of these areas considering EYO (instead of actual age), we found similar results, with presymptomatic carriers showing a significant correlation between EYO and CTh (r = -0.65 for carriers vs r = -0.33 for noncarriers, p < 0.01) (Fig. 3).

3.6. Influence of the TMEM106B genotype in the CTh – Age relationship

We did not find significant results at the vertex-wise level for the TMEM106B analyses for any of the comparisons tested. Therefore, we performed a hypothesis-driven study by focusing on the region that resulted significant in the age × group interaction. We divided the GRN carriers in groups according their TMEM106B genotype and found a significant negative correlation in the T/C carriers (r = -0.52, p < 0.01) and the T/T carriers (r = -0.47, p < 0.05), but not in the three subjects with the C/C genotype (r = -0.365, p = 0.762; Fig. 4). Only the correlation of the T/C carriers was significant and showed statistical
differences with the noncarriers group (p < 0.05). When we added the TMEM106B genotype as covariate to the multiple linear regression analysis we did not find any influence of this over the CTh, neither for presymptomatic carriers nor the noncarriers.

4. Discussion

In this study, we used data from the GENFI cohort to evaluate CTh in presymptomatic GRN mutation carriers. Although we did not find differences between carriers and noncarriers at the group-wise comparison, we found differences in the influence of aging and estimated years to onset in CTh, suggesting a greater cortical loss in presymptomatic carriers as they approach the clinical onset.

Several cross-sectional and longitudinal studies have evaluated GM loss in presymptomatic GRN mutation carriers with different methodologies, with partially divergent results. Our study, as most previous cross-sectional studies using structural MRI, did not find gray matter cortical thickness differences between presymptomatic GRN mutation carriers and controls (Borroni et al., 2012, 2008; Caroppo et al., 2015; Cash et al., 2018; Dopper et al., 2013; Fumagalli et al., 2018; Moreno et al., 2013; Panman et al., 2019). By contrast, few studies found gray matter atrophy pattern in presymptomatic carriers: Pievani and colleagues found greater GM loss in frontal areas, (Pievani et al., 2014) while Rohrer et. al. found significant differences between carriers and noncarriers.
noncarriers in the insula 15 years before the expected onset, and in the temporal and parietal lobes 10 years before the expected onset (Rohrer et al., 2015). These discrepancies in the quantification of GM loss in presymptomatic GRN mutation carriers differ from the extensive GM atrophy observed in symptomatic mutation carriers, even with a visual inspection. Several explanations have been proposed to explain this divergence of results. First, in a group cross-sectional comparison, subjects far from symptom onset are mixed with subjects close to disease onset; if CTh loss in GRN mutation carriers accelerates around the time of symptoms onset, mixing subjects at different intervals from symptom onset could cancel any apparent differences with noncarriers. In addition, the asymmetric pattern of atrophy in GRN mutation carriers might limit the differences in group-wise neuroimaging analyses.

In a previous study, in a sample of 13 presymptomatic GRN mutation carriers we observed that presymptomatic carriers presented greater age-related cortical thinning in the temporal areas when compared with controls (Moreno et al., 2013). In the present study, we expand these previous results in a much larger cohort of subjects at risk of FTD due to mutations in GRN. We found that both, presymptomatic GRN carriers and noncarriers showed a negative correlation of their CTh with age, with older subjects presenting lesser CTh. With the interaction analysis, we found a group-by-age effect in the left superior frontal cortex. In addition, the results of the multiple linear model of our study showed that, in this area, the presymptomatic carriers showed significantly greater loss of CTh with age than noncarriers. It might suggest that presymtomatic GRN carriers suffer a greater neuronal loss in this area due to neurodegeneration rather than normal aging. This is an area particularly affected in symptomatic patients (Cash et al., 2018) that have also been found to have increased rates of atrophy in longitudinal studies with presymptomatic carriers (Caroppo et al., 2015; Chen et al., 2019).

Recent work suggests that EYO has limited value in GRN families, due to a weak correlation between the individual age at onset and family age at onset (Moore et al., 2019) but better predictive markers of the disease age of onset are still lacking. Thus, as the present sample includes different GRN mutations, we also investigate the effect of EYO in

---

**Fig. 3.** Relationship between CTh and EYO: (A) Brain maps showing areas with statistical differences between carriers and noncarriers. B) Scatter plot illustrates the relationship between CThs and EYO in carriers and noncarriers. The X-axis represents the EYO. The Y-axis represents the mean CTh of the ROI covering all areas with significant differences between carriers and noncarriers. CTh: Cortical Thickness; EYO: estimated years to onset; ROI: Region of Interest.

**Fig. 4.** Scatter plot showing relationship between CTh and age in GRN carriers according their TMEM106B genotype and noncarriers in the left superior frontal cortex.
6

CTh in addition to the effect of the chronological age. When we study the correlation between CTh values and EYO, we found significant differences between presymptomatic GRN carriers and noncarriers in the right supramarginal gyrus and the banks of the rightsuperior temporal sulcus, similar to the area found in a previous work using only subjects with the same GRN mutation (Moreno et al., 2013) and thus, chronological age was interchangeable with EYO. Even if the localization of the significant clusters were not the same when EYO was used in the interaction analysis instead of age, we believe that both the dorso-frontal and the supramarginal/temporal gyrus areas are important in the disease, as they both appear at the uncorrected level. However, the fact that the magnitude of the effects is small the inclusion of a large number of covariates might hide some results when we corrected for multiple comparisons.

Variants in the TMEM106B gene have been hypothesized to be a genetic modulator of risk for GRN carriers. Previous works suggests that TMEM106B minor allele in homoygosis (C/C in rs1990622) is protective or might delay the onset in individuals with pathogenic GRN mutations. On this basis, we evaluate the influence of the TMEM106B genotype in our results. Despite the fact that we did not find differences between the different TMEM106B genotypes, we found a trend suggesting that C/C carriers might present a lower loss of CTh by age than the T/C and T/T carriers in the left superior frontal cortex. The absence of statistical differences in these analyses may be consequence of the small sample of subjects carrying the C/C genotype in our series. This would be in consonance with previous works with functional MRI that found decreased brain connectivity within the middle frontal gyrus and the left frontoparietal network in GRN carriers with the risk TMEM106B allele in front those with the protective allele (Premi et al., 2014).

The main strength of this study lies in the large sample of pre-symptomatic subjects carrying mutations in GRN. We also acknowledge some limitations. First, our age-related results are based on cross-sectional rather than longitudinal data. Although our analysis suggests a faster atrophy in presymptomatic carriers, further studies with longitudinal data are needed to corroborate this hypothesis. Another limitation is the fact that our study includes different GRN mutations which may present different ages at symptom onset, and EYO was used in some of the analysis to overcome this limitation. Finally, the TMEM106B haplotype was not available in all subjects. This fact, combined with the low frequency of the C/C haplotype in our series, limit the validity of statistical analysis performed to evaluate the influence of the TMEM106B gene in GRN carriers.

5. Conclusions

In conclusion, despite no differences in CTh were found at the whole-group comparison, the proposed linear model showed that presymptomatic GRN carriers present a significantly greater loss of CTh with age and proximity to expected disease onset. These findings suggest a faster process of neuronal loss in carriers, supporting that structural atrophy in presymptomatic carriers, further studies with longitudinal data are needed to corroborate this hypothesis. Another limitation is the fact that our study includes different GRN mutations which may present different ages at symptom onset, and EYO was used in some of the analysis to overcome this limitation. Finally, the TMEM106B haplotype was not available in all subjects. This fact, combined with the low frequency of the C/C haplotype in our series, limit the validity of statistical analysis performed to evaluate the influence of the TMEM106B gene in GRN carriers.

Role of the funding source

The funding sources have no role in the design of this study, its execution, analyses, interpretation of the data, or the decision to submit results.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgments

The authors thank all the volunteers for their participation in this study. SBE is a recipient of the Rio-Hortega post-residency grant from the Instituto de Salud Carlos III, Spain. This study was partially funded by Fundación Marató de TV3, Spain (grant no. 20143810 to RSV). The GENFI study has been supported by the Medical Research Council UK, the Italian Ministry of Health and the Canadian Institutes of Health Research as part of a Centres of Excellence in Neurodegeneration grant, as well as other individual funding to investigators. KM has received funding from an Alzheimer’s Society PhD studentship. JDR acknowledges support from the National Institute for Health Research (NIHR) Queen Square Dementia Biomedical Research Unit and the University College London Hospitals Biomedical Research Centre, the Leonard Wolfson Experimental Neurology Centre, the UK Dementia Research Institute, Alzheimer’s Research UK, the Brain Research Trust and the Wolfson Foundation. JCvS was supported by the Dioraphte Foundation grant 09-02-03-00, the Association for Frontotemporal Dementias Research Grant 2009, The Netherlands Organization for Scientific Research (NWO) grant HCM 056-13-018, ZonMw Memorabel (Delta-plan Demente, project number 733 051 042), Alzheimer Nederland and the Bluefield project. CG have received funding from JPND-Prefrontals VR Dnr 529-2014-7504, VR: 2015-02926, and 2018-02754, the Swedish FTD Initiative-Schöning Foundation, Alzheimer Foundation, Brain Foundation and Stockholm County Council ALF. DG has received support from the EU Joint Programme – Neurodegenerative Disease Research (JPND) and the Italian Ministry of Health (PreFrontALS) grant 733051042. JDR is funded by the Wellcome Trust (103838) and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. MM has received funding from a Canadian Institutes of Health Research operating grant and the Weston Brain Institute and Ontario Brain Institute. RV has received funding from the Mady Brownes Fund for Research into Frontotemporal Dementia. EF has received funding from a CIHR grant #327387. JDR is an MRC Clinician Scientist (MR/M008525/1) and has received funding from the NIHR Rare Diseases Translational Research Collaboration (BRC149/NS/MH), the Bluefield Project and the Association for Frontotemporal Degeneration. MS was supported by a grant 779257 “Solve-RD” from the Horizon 2020 research and innovation programme.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jicl.2020.102540.

References:


